IMAB Capital Surpluse vs Common Stock Shares Outstanding Analysis
IMAB Stock | USD 0.94 0.02 2.08% |
I Mab financial indicator trend analysis is infinitely more than just investigating I Mab recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether I Mab is a good investment. Please check the relationship between I Mab Capital Surpluse and its Common Stock Shares Outstanding accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in I Mab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.
Capital Surpluse vs Common Stock Shares Outstanding
Capital Surpluse vs Common Stock Shares Outstanding Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of I Mab Capital Surpluse account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have almost identical trend.
The correlation between I Mab's Capital Surpluse and Common Stock Shares Outstanding is 0.93. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of I Mab, assuming nothing else is changed. The correlation between historical values of I Mab's Capital Surpluse and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of I Mab are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Capital Surpluse i.e., I Mab's Capital Surpluse and Common Stock Shares Outstanding go up and down completely randomly.
Correlation Coefficient | 0.93 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Capital Surpluse
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most indicators from I Mab's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into I Mab current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in I Mab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.At present, I Mab's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 17.21, whereas Tax Provision is forecasted to decline to 0.00.
2022 | 2023 | 2024 (projected) | Interest Expense | 1.3K | 101.9K | 96.8K | Depreciation And Amortization | 25.3M | 23.9M | 20.6M |
I Mab fundamental ratios Correlations
Click cells to compare fundamentals
I Mab Account Relationship Matchups
High Positive Relationship
High Negative Relationship
I Mab fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.7B | 6.3B | 5.6B | 4.1B | 2.6B | 3.7B | |
Short Long Term Debt Total | 132.5M | 13.6M | 112.5M | 75.0M | 18.9M | 17.9M | |
Other Current Liab | 531.7M | 567.4M | 593.3M | 637.3M | 371.9M | 463.9M | |
Total Current Liabilities | 588.5M | 576.1M | 624.0M | 659.7M | 411.8M | 534.5M | |
Total Stockholder Equity | (2.0B) | 5.6B | 4.6B | 3.0B | 242.4M | 230.3M | |
Other Liab | 2.5M | 3.9M | 125.0M | 335.8M | 386.2M | 405.5M | |
Net Tangible Assets | (1.3B) | (2.3B) | 5.3B | 4.3B | 5.0B | 5.2B | |
Property Plant And Equipment Net | 46.5M | 40.3M | 158.5M | 124.0M | 11.7M | 11.1M | |
Current Deferred Revenue | 3.9M | 7.5M | 2.4M | 8.7M | 32.6M | 34.2M | |
Net Debt | (1.0B) | (4.7B) | (3.4B) | (3.1B) | (2.0B) | (2.1B) | |
Retained Earnings | (2.5B) | (2.0B) | (4.4B) | (6.8B) | (8.3B) | (7.9B) | |
Accounts Payable | 67.7M | (3.9M) | (2.4M) | (33.1M) | (29.8M) | (28.3M) | |
Cash | 1.1B | 4.8B | 3.5B | 3.2B | 302.1M | 287.0M | |
Non Current Assets Total | 376.3M | 990.1M | 847.7M | 447.2M | 276.3M | 262.5M | |
Non Currrent Assets Other | 18.3M | 2.0M | 26.6M | 10.9M | 246.2M | 258.5M | |
Other Assets | 18.3M | 2.0M | 26.6M | 237.3M | 272.9M | 286.6M | |
Cash And Short Term Investments | 1.2B | 4.8B | 4.3B | 3.4B | 2.3B | 2.9B | |
Net Receivables | 55.9M | 130.5M | 286.9M | 4.8M | 18.0M | 17.1M | |
Common Stock Shares Outstanding | 57.8M | 68.4M | 76.0M | 82.5M | 83.2M | 71.8M | |
Short Term Investments | 32M | 31.5M | 753.2M | 235.4M | 143.2M | 269.9M | |
Liabilities And Stockholders Equity | 1.7B | 6.3B | 5.6B | 4.1B | 2.6B | 3.7B | |
Non Current Liabilities Total | 3.2B | 130.5M | 417.6M | 405.6M | 483.0M | 458.8M | |
Capital Lease Obligations | 14.3M | 13.6M | 112.5M | 56.0M | 45.0M | 37.9M | |
Inventory | (55.9M) | (422.9M) | 27.2M | (80.3M) | (18.0M) | (18.9M) | |
Other Current Assets | 191.8M | 195.5M | 190.8M | 172.5M | 47.1M | 44.8M | |
Other Stockholder Equity | (2.7B) | 5.7B | 9.1B | 1.2B | 8.3B | 8.7B | |
Total Liab | 3.8B | 706.6M | 1.0B | 1.1B | 894.8M | 1.4B | |
Net Invested Capital | (1.9B) | 5.6B | 4.6B | 3.0B | 1.8B | 1.9B | |
Property Plant And Equipment Gross | 46.5M | 40.3M | 158.5M | 124.0M | 156.4M | 90.5M | |
Total Current Assets | 1.4B | 5.3B | 4.8B | 3.6B | 2.3B | 3.2B | |
Accumulated Other Comprehensive Income | 70.1M | (50.8M) | (186.5M) | 216.7M | 298.3M | 313.2M | |
Net Working Capital | 772.8M | 4.8B | 4.2B | 3.0B | 1.9B | 2.6B | |
Short Term Debt | 56.8M | (33.6M) | 30.7M | 22.4M | 7.3M | 7.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether I Mab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of I Mab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of I Mab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on I Mab Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in I Mab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of I Mab. If investors know IMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about I Mab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.16) | Revenue Per Share 0.043 | Quarterly Revenue Growth (0.62) | Return On Assets (0.29) | Return On Equity (0.72) |
The market value of I Mab is measured differently than its book value, which is the value of IMAB that is recorded on the company's balance sheet. Investors also form their own opinion of I Mab's value that differs from its market value or its book value, called intrinsic value, which is I Mab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because I Mab's market value can be influenced by many factors that don't directly affect I Mab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between I Mab's value and its price as these two are different measures arrived at by different means. Investors typically determine if I Mab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, I Mab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.